ID   A2780/ACR6
AC   CVCL_D156
SY   ACR6
DR   cancercelllines; CVCL_D156
DR   Wikidata; Q54606586
RX   PubMed=12726863;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 15
//
RX   PubMed=12726863; DOI=10.1016/S1535-6108(03)00058-8;
RA   Sherman-Baust C.A., Weeraratna A.T., Rangel L.B.A., Pizer E.S.,
RA   Cho K.R., Schwartz D.R., Shock T., Morin P.J.;
RT   "Remodeling of the extracellular matrix through overexpression of
RT   collagen VI contributes to cisplatin resistance in ovarian cancer
RT   cells.";
RL   Cancer Cell 3:377-386(2003).
//